US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TuHURA Biosciences, Inc.

2.81

-0.0800-2.77%

Post-market: 2.80-0.0100-0.36%17:42 EDT

Volume:70.89K

Turnover:201.26K

Market Cap:122.74M

PE:-3.04

High:2.94

Open:2.91

Low:2.70

Close:2.89

Loading ...

Overview Company News Filings

TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody

BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private Offering

Tuhura Biosciences-Plans to Use Net Proceeds From Offering to Fund Cash Requirements for Closing Proposed Merger With Kineta

THOMSON REUTERS

Tuhura Biosciences Inc -Secures $12.5 Mln of Commitments in a Private Offering

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025

Tuhura Biosciences Presents Ifx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

THOMSON REUTERS

TuHURA Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

TuHURA Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate

TuHURA Biosciences Reports Increased R&D and Administrative Expenses for Q1 2025; No Significant Revenue or Profit Data Provided

BRIEF-TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update

Tuhura Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS

TuHURA Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview

TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma

Tuhura Biosciences Inc - FDA Agreement Reached to Lift Partial Clinical Hold on Phase 3 Trial of Ifx-2.0

THOMSON REUTERS

Tuhura Biosciences, Inc. Initiates Phase 1B/2a Study of Ifx-Hu2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (Mccup)

THOMSON REUTERS

Tuhura Biosciences Inc: Anticipates Initiating Phase 3 Registrational Trial of Ifx-2.0 in Q2

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HURA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.81,"timestamp":1749240000000,"preClose":2.89,"halted":0,"volume":70891,"hourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.81,"latestTime":"17:42 EDT","volume":358,"amount":1006.4300418,"timestamp":1749246126009},"delay":0,"floatShares":21286907,"shares":43680396,"eps":-0.924572,"marketStatus":"Post-Mkt","change":-0.08,"latestTime":"06-06 18:00:45 EDT","open":2.91,"high":2.9415,"low":2.7,"amount":201257.53569559997,"amplitude":0.083564,"askPrice":3.04,"askSize":100,"bidPrice":2.8,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-0.924572,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749254400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.89,"preHourTrading":{"tag":"盘前","latestPrice":2.89,"preClose":2.89,"latestTime":"09:22 EDT","volume":593,"amount":1782.4699395,"timestamp":1749216125786},"postHourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.81,"latestTime":"17:42 EDT","volume":358,"amount":1006.4300418,"timestamp":1749246126009},"volumeRatio":0.476209},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":21286907,"roa":"-90.68%","roe":"-332.67%","lyrEps":-1.213628,"volumeRatio":0.476209,"shares":43680396,"dividePrice":0,"high":2.9415,"amplitude":0.083564,"preClose":2.89,"low":2.7,"week52Low":1.8,"pbRate":"12.82","week52High":13.125,"institutionHeld":0,"latestPrice":2.81,"committee":-0.769912,"eps":-0.924572,"divideRate":0,"volume":70891,"delay":0,"ttmEps":-0.924572,"open":2.91,"prevYearClose":4.09,"prevWeekClose":3.06,"prevMonthClose":3.06,"prevQuarterClose":3.23,"fiveDayClose":3.06,"twentyDayClose":3.93,"sixtyDayClose":2.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541931838","title":"TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2541931838","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541931838?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:43","pubTimestamp":1749242589,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody. TuHURA Biosciences, Inc. has announced plans to initiate a Phase 3 accelerated approval trial for its treatment IFx-2.0, targeting 40% enrollment by the end of 2025. The company has secured $12.5 million in commitments through a private offering and an additional $3.0 million from warrant exercises to support this initiative. The funding will also facilitate the acquisition and initiation of a Phase 2 trial in NPM1 mutated acute myeloid leukemia  through the closing of a merger with Kineta, Inc. Currently, there are no results available from these studies, as the trials and acquisitions are in the planning and initiation stages.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL95Y9sW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KANT","HURA","BK4139"],"gpt_icon":0},{"id":"2540777769","title":"BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2540777769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540777769?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:11","pubTimestamp":1748959888,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private OfferingJune 3 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC -SECURES $12.5 MILLION OF COMMITMENTS IN A PRIVATE OFFERINGTUHURA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2540777933","title":"Tuhura Biosciences-Plans to Use Net Proceeds From Offering to Fund Cash Requirements for Closing Proposed Merger With Kineta","url":"https://stock-news.laohu8.com/highlight/detail?id=2540777933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540777933?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2540677756","title":"Tuhura Biosciences Inc -Secures $12.5 Mln of Commitments in a Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2540677756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540677756?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2540977763","title":"Press Release: TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2540977763","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540977763?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959080,"startTime":"0","endTime":"0","summary":"Secures $12.5 million of commitments in a private offering. Secures an additional $3.0 million through payment of cash exercise price of warrants. -- Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a. novel VISTA inhibiting antibody through closing of Kineta merger. Under the definitive agreement, approximately $9.0 million of the total offering amount will be purchased in four equal tranches based on the Company's achievement of certain milestones , and the remaining $3.5 million is required to be purchased and funded by December 31, 2025. One-fourth of the Initial Funding Amount will be purchased and funded at the initial closing of the offering, which is anticipated to be held on June 4, 2025 , with the remaining three tranches of the Initial Funding Amount to be purchased and funded based on the achievement of the following three milestones  if and when the applicable milestone is achieved:. -- One-fourth of the Initial Funding Amount will be purchased and funded","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","HURA","BK4022","EQR","ADC","BK4215","BK4588","BK4232","BK4139","R","BK4585"],"gpt_icon":0},{"id":"2540764760","title":"TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540764760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540764760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:03","pubTimestamp":1748865800,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL9Bwhcw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2540602457","title":"Tuhura Biosciences Presents Ifx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540602457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540602457?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:03","pubTimestamp":1748865783,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA9MSBXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2535039637","title":"TuHURA Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535039637","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535039637?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:22","pubTimestamp":1747394520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 07:22 ET (11:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2535837093","title":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535837093","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535837093?lang=en_us&edition=fundamental","pubTime":"2025-05-16 09:09","pubTimestamp":1747357787,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryTuHURA Biosciences Inc HURA.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO019:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2535680822","title":"TuHURA Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535680822","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535680822?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:37","pubTimestamp":1747341432,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 62.5 percent increase over losses of $(0.40) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45453804/tuhura-biosciences-q1-eps-0-15-misses-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2535080832","title":"TuHURA Biosciences Reports Increased R&D and Administrative Expenses for Q1 2025; No Significant Revenue or Profit Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2535080832","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535080832?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:27","pubTimestamp":1747340837,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Reports Increased R&D and Administrative Expenses for Q1 2025; No Significant Revenue or Profit Data Provided. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL54Qg52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","KANT"],"gpt_icon":0},{"id":"2535887004","title":"BRIEF-TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535887004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535887004?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:22","pubTimestamp":1747340532,"startTime":"0","endTime":"0","summary":"BRIEF-TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate UpdateMay 15 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES, INC. REPORTS FIRST QUARTER 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA4HRGFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2535870685","title":"Tuhura Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535870685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535870685?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:10","pubTimestamp":1747339804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA4HRGFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2534878465","title":"TuHURA Biosciences Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534878465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534878465?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:00","pubTimestamp":1746824420,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of10cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to report resultson May 12 (estimated) for the period ending Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2533760586","title":"TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2533760586","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533760586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446495,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. Announces Initiation of Phase 1b/2a Trial for IFx-Hu2.0 as Adjunctive Therapy in Metastatic Merkel Cell Carcinoma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on May 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nNDLlzZBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2533858625","title":"Tuhura Biosciences Inc - FDA Agreement Reached to Lift Partial Clinical Hold on Phase 3 Trial of Ifx-2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2533858625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533858625?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2533586828","title":"Tuhura Biosciences, Inc. Initiates Phase 1B/2a Study of Ifx-Hu2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (Mccup)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586828?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2533586211","title":"Tuhura Biosciences Inc:  Anticipates Initiating Phase 3 Registrational Trial of Ifx-2.0 in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586211?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA17NP03:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2525891539","title":"Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891539?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:18","pubTimestamp":1744114680,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting. TAMPA, Fla., April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research  Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda  compared to K","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4139","HURA","KANT","BK4022"],"gpt_icon":0},{"id":"2525043506","title":"BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043506","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043506?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:02","pubTimestamp":1744030944,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice PresidentApril 7 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES, INC. APPOINTS DR. BERTRAND LE BOURDONNEC A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUA19NJVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37},{"market":"US","date":"2024-10-18","symbol":"HURA","defaultRemindTime":1729258200000,"type":"split","dateTimestamp":1729224000000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2024-10-07","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728273600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1747454400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2025-06-05","current":-5.240636,"percent":0.926174,"low":-15.284879,"twenty":-10.314768,"median":-8.085649,"eighty":-6.631017,"high":-4.329639,"avg":-8.452206,"sd":2.355711,"marketCap":123178716},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-05","current":-5.240636,"twenty":-10.314768,"median":-8.085649,"eighty":-6.631017,"marketCap":123178716}],"updateTime":1749215617806}}}